Prescription medicine
Maribavir Brand names: Livtencity
Maribavir (Livtencity) is a prescription medicine with an FDA approval on record since 2021. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the maribavir FDA label on DailyMed (effective January 27, 2026, Takeda Pharmaceuticals America, Inc.); the NDA 215596 record on Drugs@FDA; every maribavir label on DailyMed.
Highlights of the record
FDA label of January 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageLIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ].
Forms and strengths
- 200 mg
Coated tablet.
On the market
- Earliest approval on file
- November 23, 2021 Livtencity, Takeda Pharms Usa; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 11, 2043 Livtencity tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,410 through July 30, 2026
What is maribavir used for?
From the label: indications and usageLIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ]. […]
FDA pharmacologic class: Cytomegalovirus pUL97 Kinase Inhibitor.
Source: FDA drug label (Livtencity), Takeda Pharmaceuticals America, Inc., effective January 27, 2026 (SPL set c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0), via openFDA; the full label on DailyMed
Is there a generic for maribavir (Livtencity)?
No generic maribavir is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 8 patents for Livtencity tablets: the compound patent runs to October 11, 2043. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2021 earliest approval on file
- 2043 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the maribavir label say about other medicines?
The maribavir label names 19 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Caffeine | drug interactions | Drugs without Clinically Significant Interactions with LIVTENCITY No clinically significant interactions were observed in clinical drug-drug interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
| Carbamazepine | drug interactions | Concomitant Drug Class/Drug Name: Carbamazepine; Effect on Concentration: ↓ Maribavir; Clinical Comments: A dose adjustment of LIVTENCITY to 800 mg twice daily is recommended when coadministered with carbamazepine. |
| Cyclosporine | drug interactions | Concomitant Drug Class/Drug Name: Cyclosporine; Effect on Concentration: ↑ Cyclosporine; Clinical Comments: Frequently monitor cyclosporine levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed. |
| Dextromethorphan | drug interactions | Drugs without Clinically Significant Interactions with LIVTENCITY No clinically significant interactions were observed in clinical drug-drug interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
| Digoxin | drug interactions | Concomitant Drug Class/Drug Name: Digoxin The interaction between LIVTENCITY and the concomitant drug was evaluated in a clinical study [see ].; Effect on Concentration: ↑ Digoxin; Clinical Comments: Use caution when LIVTENCITY and digoxin are coadministered. Monitor serum digoxin concentrations. … |
| Everolimus | drug interactions | Concomitant Drug Class/Drug Name: Everolimus; Effect on Concentration: ↑ Everolimus; Clinical Comments: Frequently monitor everolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed. |
| Ganciclovir | drug interactions | Coadministered with Ganciclovir or Valganciclovir LIVTENCITY is not recommended to be coadministered with valganciclovir/ganciclovir (vGCV/GCV). |
| Ketoconazole | drug interactions | Drugs without Clinically Significant Interactions with LIVTENCITY No clinically significant interactions were observed in clinical drug-drug interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
| Midazolam | drug interactions | Drugs without Clinically Significant Interactions with LIVTENCITY No clinically significant interactions were observed in clinical drug-drug interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
| Phenobarbital | drug interactions | When coadministered with the moderate CYP3A4 inducers rifabutin (antimycobacterial) or phenobarbital (anticonvulsant), a dose adjustment is recommended. |
| Phenytoin | drug interactions | Concomitant Drug Class/Drug Name: Phenytoin; Effect on Concentration: ↓ Maribavir; Clinical Comments: A dose adjustment of LIVTENCITY to 1,200 mg twice daily is recommended when coadministration with phenytoin. |
| Rifabutin | drug interactions | When coadministered with the moderate CYP3A4 inducers rifabutin (antimycobacterial) or phenobarbital (anticonvulsant), a dose adjustment is recommended. |
| Rifampin | drug interactions | Concomitant Drug Class/Drug Name: Rifampin; Effect on Concentration: ↓ Maribavir; Clinical Comments: Coadministration of LIVTENCITY and rifampin is not recommended due to potential for a decrease in efficacy of LIVTENCITY. |
| Rosuvastatin | drug interactions | Concomitant Drug Class/Drug Name: Rosuvastatin; Effect on Concentration: ↑ Rosuvastatin; Clinical Comments: The patient should be closely monitored for rosuvastatin-related events, especially the occurrence of myopathy and rhabdomyolysis. |
Every other medicine the maribavir label names
| Medicine named | Section | What the label says |
|---|---|---|
| Sirolimus | drug interactions | Concomitant Drug Class/Drug Name: Sirolimus; Effect on Concentration: ↑ Sirolimus; Clinical Comments: Frequently monitor sirolimus levels throughout treatment with LIVTENCITY, especially following … |
| Tacrolimus | drug interactions | Concomitant Drug Class/Drug Name: Tacrolimus; Effect on Concentration: ↑ Tacrolimus; Clinical Comments: Frequently monitor tacrolimus levels throughout treatment with LIVTENCITY, especially following … |
| Valganciclovir | drug interactions | Coadministered with Ganciclovir or Valganciclovir LIVTENCITY is not recommended to be coadministered with valganciclovir/ganciclovir (vGCV/GCV). |
| Voriconazole | drug interactions | … studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
| Warfarin | drug interactions | … interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam [see Clinical Pharmacology (12.3) ]. |
Source: FDA drug label (Livtencity), Takeda Pharmaceuticals America, Inc., effective January 27, 2026 (SPL set c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0), via openFDA; the full label on DailyMed
What do FAERS reports show for maribavir?
The FDA Adverse Event Reporting System holds 2,410 reports that list maribavir among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 526 are coded as a death and 1,102 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Maribavir side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other